HSSynergy, a hierarchical substructure-aware deep learning framework for predicting anticancer drug synergy, introduces a Scale-Aware Masked Attention mechanism that enforces precise layer-wise alignment, and utilizes hierarchical grouping with mask constraints to achieves same-scale focusing while shielding against cross-scale noise.
Abstract
Combination therapy offers a promising strategy for cancer treatment by reducing toxicity and overcoming drug resistance. However, existing substructure-based prediction methods may struggle to effectively capture the scale-specific features of substructure interactions and often overlook cell-line-specific substructure selection, which can limit mechanistic interpretability. To address this issue, we propose HSSynergy, a hierarchical substructure-aware deep learning framework for predicting anticancer drug synergy. It first employs Graph Attention-Convolution Fusion Module to adaptively extract multi-scale substructure features from molecular graphs. Rather than indiscriminately mixing features, it introduces a Scale-Aware Masked Attention mechanism that enforces precise layer-wise alignment, and utilizes hierarchical grouping with mask constraints to achieves same-scale focusing while shielding against cross-scale noise. Furthermore, shifting away from passive cell line representations, a Cell-Active Cross-Attention mechanism models the active selection of specific substructures by heterogeneous cancer cells, capturing precise drug-cell contexts. Rigorous evaluations on two benchmark datasets show that HSSynergy achieves superior performance compared to state-of-the-art methods with robust generalization to unseen drugs and cell lines. Beyond predictive metrics, it provides mechanistic interpretability insights, revealing the hierarchical emergence of substructures and accurately pinpointing literature-validated functional groups driving synergy in specific drug combinations. Notably, several novel synergistic combinations predicted by HSSynergy are supported by existing literature and clinical evidence, suggesting its potential utility in aiding anticancer drug discovery.
HSSynergy (i) Scale-Aware Masked Attention restricts substructure interactions within scale groups to reduce cross-scale noise. (ii) Cell-Active Cross-Attention models dynamic, cell-specific substructure selection instead of static cell-line fusion. (iii)Hierarchical attention links synergy predictions to pharmacologically functional groups.
MKASynergy, an adaptive drug synergy prediction method based on a mixture-of-experts kernel mechanism, achieves competitive predictive performance and visualization analysis confirms the model’s effectiveness in feature decoupling and helps interpret latent drug synergistic mechanisms.
Cundong Lin, Jiancheng Ni, Ying Yang et al.· Network Modeling Analysis in...· 0 citations
Drug repositioning has emerged as an attractive drug development strategy with deep learning-based computational methods showing great potential in predicting Drug-Disease Associations (DDAs). However, dominant computational paradigms typically rely on Random Negative Sampling (RNS) and static embedding fusion, leading...
Ke-Rui Xu, Ke-Yuan Xu, Shu-Hui Yin et al.· Proceedings of the Thirty-Fi...· 0 citations
Results indicate that FragSyn, through the synergistic design of fragment-level representation and cellular context awareness, provides an effective and interpretable new approach to synergistic drug combination prediction.
Li-Feng Shao, Jianqiang Sun, Hong-Zhan Ma et al.· Journal of Chemical Informat...· 0 citations
Drug-target affinity prediction provides a computational basis for virtual screening and drug repositioning optimization by estimating the binding strength between compounds and target proteins. Existing deep learning methods have evolved from early SMILES/amino acid sequence modeling to graph neural networks and multi...
Yu-Ning Liu, Guang-Ze Wang, Dan Liu et al.· European journal of medicina...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.